Epigallocatechin-3-gallate induces the apoptosis of hepatocellular carcinoma LM6 cells but not non-cancerous liver cells

Zhang,Y, Duan,W, Owusu,L, Wu,D and Xin,Y 2014, Epigallocatechin-3-gallate induces the apoptosis of hepatocellular carcinoma LM6 cells but not non-cancerous liver cells, International Journal of Molecular Medicine, vol. 35, no. 1, pp. 117-124, doi: 10.3892/ijmm.2014.1988.

Attached Files
Name Description MIMEType Size Downloads

Title Epigallocatechin-3-gallate induces the apoptosis of hepatocellular carcinoma LM6 cells but not non-cancerous liver cells
Author(s) Zhang,Y
Duan,WORCID iD for Duan,W orcid.org/0000-0001-5782-9184
Owusu,L
Wu,D
Xin,Y
Journal name International Journal of Molecular Medicine
Volume number 35
Issue number 1
Start page 117
End page 124
Total pages 8
Publisher Spandidos Publications
Place of publication Athens, Greece
Publication date 2014-10-31
ISSN 1791-244X
Keyword(s) Apoptosis
Epigallocatechin-3-gallate
Hepatocellular carcinoma
Science & Technology
Life Sciences & Biomedicine
Medicine, Research & Experimental
Research & Experimental Medicine
GREEN TEA POLYPHENOLS
CYTOCHROME-C RELEASE
CASPASE ACTIVATION
GENE-EXPRESSION
CYCLE ARREST
DNA DAMAGE
CANCER
GALLATE
INHIBITION
PROTEINS
Summary Epigallocatechin-3-gallate (EGCG) is a constituent of green tea and has been associated with anticancer activity. In the present study, the inhibitory effect of EGCG on human hepatocellular cancer cells was examined by cell viability assay, in vitro apoptosis assay and cell cycle analysis. In addition, gene expression was measured to elucidate the molecular mechanisms of action of EGCG by mitochondrial membrane potential (MMP) determination and western blot analysis. We demonstrated that EGCG induced apoptosis, decreased mitochondrial membrane potential and promoted G0/G1 phase cell cycle arrest of HCCLM6 cells but not that of non-cancerous liver cells (HL-7702). The EGCG-induced apoptosis of HCCLM6 cells was associated with a significant decrease in Bcl-2 and NF-κB expression. In addition, the expression of Bax, p53, caspase-9 and caspase-3 increased, and cytochrome c was released. These results suggest that EGCG inhibits the progression of cancer through cytocidal activity and that it is a potential therapeutic compound for hepatocellular carcinoma (HCC).
Language eng
DOI 10.3892/ijmm.2014.1988
Field of Research 111299 Oncology and Carcinogenesis not elsewhere classified
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2014, Spandidos Publications
Persistent URL http://hdl.handle.net/10536/DRO/DU:30072393

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 12 times in TR Web of Science
Scopus Citation Count Cited 16 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 224 Abstract Views, 3 File Downloads  -  Detailed Statistics
Created: Tue, 21 Apr 2015, 11:48:44 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.